Literature DB >> 21228066

Increased nicotinic acetylcholine receptor protein underlies chronic nicotine-induced up-regulation of nicotinic agonist binding sites in mouse brain.

Michael J Marks1, Tristan D McClure-Begley, Paul Whiteaker, Outi Salminen, Robert W B Brown, John Cooper, Allan C Collins, Jon M Lindstrom.   

Abstract

Chronic nicotine treatment elicits a brain region-selective increase in the number of high-affinity agonist binding sites, a phenomenon termed up-regulation. Nicotine-induced up-regulation of α4β2-nicotinic acetylcholine receptors (nAChRs) in cell cultures results from increased assembly and/or decreased degradation of nAChRs, leading to increased nAChR protein levels. To evaluate whether the increased binding in mouse brain results from an increase in nAChR subunit proteins, C57BL/6 mice were treated with nicotine by chronic intravenous infusion. Tissue sections were prepared, and binding of [(125)I]3-((2S)-azetidinylmethoxy)-5-iodo-pyridine (A85380) to β2*-nAChR sites, [(125)I]monoclonal antibody (mAb) 299 to α4 nAChR subunits, and [(125)I]mAb 270 to β2 nAChR subunits was determined by quantitative autoradiography. Chronic nicotine treatment dose-dependently increased binding of all three ligands. In regions that express α4β2-nAChR almost exclusively, binding of all three ligands increased coordinately. However, in brain regions containing significant β2*-nAChR without α4 subunits, relatively less increase in mAb 270 binding to β2 subunits was observed. Signal intensity measured with the mAbs was lower than that with [(125)I]A85380, perhaps because the small ligand penetrated deeply into the sections, whereas the much larger mAbs encountered permeability barriers. Immunoprecipitation of [(125)I]epibatidine binding sites with mAb 270 in select regions of nicotine-treated mice was nearly quantitative, although somewhat less so with mAb 299, confirming that the mAbs effectively recognize their targets. The patterns of change measured using immunoprecipitation were comparable with those determined autoradiographically. Thus, increases in α4β2*-nAChR binding sites after chronic nicotine treatment reflect increased nAChR protein.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21228066      PMCID: PMC3063733          DOI: 10.1124/jpet.110.178236

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

Review 1.  Why doesn't nicotinic ACh receptor immunoreactivity knock out?

Authors:  Ian W Jones; Susan Wonnacott
Journal:  Trends Neurosci       Date:  2005-07       Impact factor: 13.837

2.  Evaluating the suitability of nicotinic acetylcholine receptor antibodies for standard immunodetection procedures.

Authors:  N Moser; N Mechawar; I Jones; A Gochberg-Sarver; A Orr-Urtreger; M Plomann; R Salas; B Molles; L Marubio; U Roth; U Maskos; U Winzer-Serhan; J-P Bourgeois; A-M Le Sourd; M De Biasi; H Schröder; J Lindstrom; A Maelicke; J-P Changeux; A Wevers
Journal:  J Neurochem       Date:  2007-04-10       Impact factor: 5.372

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Nicotine acts as a pharmacological chaperone to up-regulate human alpha4beta2 acetylcholine receptors.

Authors:  A Kuryatov; J Luo; J Cooper; J Lindstrom
Journal:  Mol Pharmacol       Date:  2005-09-23       Impact factor: 4.436

5.  Deletion of the beta 2 nicotinic acetylcholine receptor subunit alters development of tolerance to nicotine and eliminates receptor upregulation.

Authors:  Sarah E McCallum; Allan C Collins; Richard Paylor; Michael J Marks
Journal:  Psychopharmacology (Berl)       Date:  2005-07-02       Impact factor: 4.530

6.  Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies.

Authors:  D C Perry; M I Dávila-García; C A Stockmeier; K J Kellar
Journal:  J Pharmacol Exp Ther       Date:  1999-06       Impact factor: 4.030

7.  Nicotine upregulates its own receptors through enhanced intracellular maturation.

Authors:  Jérôme Sallette; Stéphanie Pons; Anne Devillers-Thiery; Martine Soudant; Lia Prado de Carvalho; Jean-Pierre Changeux; Pierre Jean Corringer
Journal:  Neuron       Date:  2005-05-19       Impact factor: 17.173

8.  Chronic nicotine exposure upregulates nicotinic receptors by a novel mechanism.

Authors:  Yolanda F Vallejo; Bruno Buisson; Daniel Bertrand; William N Green
Journal:  J Neurosci       Date:  2005-06-08       Impact factor: 6.167

9.  Immunolabeling demonstrates the interdependence of mouse brain alpha4 and beta2 nicotinic acetylcholine receptor subunit expression.

Authors:  Paul Whiteaker; John F Cooper; Outi Salminen; Michael J Marks; Tristan D McClure-Begley; Robert W B Brown; Allan C Collins; Jon M Lindstrom
Journal:  J Comp Neurol       Date:  2006-12-20       Impact factor: 3.215

10.  Chronic nicotine differentially regulates alpha6- and beta3-containing nicotinic cholinergic receptors in rat brain.

Authors:  David C Perry; Danyan Mao; Allison B Gold; J Michael McIntosh; John C Pezzullo; Kenneth J Kellar
Journal:  J Pharmacol Exp Ther       Date:  2007-04-19       Impact factor: 4.030

View more
  39 in total

1.  Regulation of the distribution and function of [(125)I]epibatidine binding sites by chronic nicotine in mouse embryonic neuronal cultures.

Authors:  Cristian A Zambrano; Rakel M Salamander; Allan C Collins; Sharon R Grady; Michael J Marks
Journal:  J Pharmacol Exp Ther       Date:  2012-04-24       Impact factor: 4.030

2.  Spectral confocal imaging of fluorescently tagged nicotinic receptors in knock-in mice with chronic nicotine administration.

Authors:  Anthony Renda; Raad Nashmi
Journal:  J Vis Exp       Date:  2012-02-10       Impact factor: 1.355

Review 3.  Nicotinic acetylcholine receptors: upregulation, age-related effects and associations with drug use.

Authors:  W E Melroy-Greif; J A Stitzel; M A Ehringer
Journal:  Genes Brain Behav       Date:  2015-12-23       Impact factor: 3.449

4.  Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism.

Authors:  Jacob G Dubroff; Robert K Doot; Mary Falcone; Robert A Schnoll; Riju Ray; Rachel F Tyndale; Arthur L Brody; Catherine Hou; Alexander Schmitz; Caryn Lerman
Journal:  J Nucl Med       Date:  2015-08-13       Impact factor: 10.057

5.  Nicotinic receptors regulate the dynamic range of dopamine release in vivo.

Authors:  Jessica L Koranda; Jackson J Cone; Daniel S McGehee; Mitchell F Roitman; Jeff A Beeler; Xiaoxi Zhuang
Journal:  J Neurophysiol       Date:  2013-10-02       Impact factor: 2.714

Review 6.  Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.

Authors:  Maryka Quik; Xiomara A Perez; Sharon R Grady
Journal:  Biochem Pharmacol       Date:  2011-06-13       Impact factor: 5.858

7.  Effects of chronic nicotine on heteromeric neuronal nicotinic receptors in rat primary cultured neurons.

Authors:  Ermelinda Lomazzo; Gregory P Hussmann; Barry B Wolfe; Robert P Yasuda; David C Perry; Kenneth J Kellar
Journal:  J Neurochem       Date:  2011-09-01       Impact factor: 5.372

Review 8.  Proteins and chemical chaperones involved in neuronal nicotinic receptor expression and function: an update.

Authors:  Arianna Crespi; Sara Francesca Colombo; Cecilia Gotti
Journal:  Br J Pharmacol       Date:  2017-04-19       Impact factor: 8.739

9.  Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density.

Authors:  Arthur L Brody; Alexey G Mukhin; Michael S Mamoun; Maggie Kozman; Jonathan Phuong; Meaghan Neary; Trinh Luu; Mark A Mandelkern
Journal:  Neuropsychopharmacology       Date:  2013-02-21       Impact factor: 7.853

10.  Differential effects of withdrawal from intermittent and continuous nicotine exposure on reward deficit and somatic aspects of nicotine withdrawal and expression of α4β2* nAChRs in Wistar male rats.

Authors:  Svetlana Semenova; Xinchun Jin; Tristan D McClure-Begley; Matthew Philip Tadman; Michael J Marks; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2018-06-14       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.